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Abstract
Background: The question of whether a score for a specific antiretroviral (e.g. lopinavir/r in this analysis) that improves
prediction of viral load response given by existing expert-based interpretation systems (IS) could be derived from analyzing
the correlation between genotypic data and virological response using statistical methods remains largely unanswered.
Methods and Findings: We used the data of the patients from the UK Collaborative HIV Cohort (UK CHIC) Study for whom
genotypic data were stored in the UK HIV Drug Resistance Database (UK HDRD) to construct a training/validation dataset of
treatment change episodes (TCE). We used the average square error (ASE) on a 10-fold cross-validation and on a test dataset
(the EuroSIDA TCE database) to compare the performance of a newly derived lopinavir/r score with that of the 3 most
widely used expert-based interpretation rules (ANRS, HIVDB and Rega). Our analysis identified mutations V82A, I54V, K20I
and I62V, which were associated with reduced viral response and mutations I15V and V91S which determined lopinavir/r
hypersensitivity. All models performed equally well (ASE on test ranging between 1.1 and 1.3, p = 0.34).
Conclusions: We fully explored the potential of linear regression to construct a simple predictive model for lopinavir/r-
based TCE. Although, the performance of our proposed score was similar to that of already existing IS, previously
unrecognized lopinavir/r-associated mutations were identified. The analysis illustrates an approach of validation of expert-
based IS that could be used in the future for other antiretrovirals and in other settings outside HIV research.
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Introduction
The treatment of human immunodeficiency virus (HIV)-positive
individuals with combination antiretroviral therapy (cART) has
significantly reduced the morbidity and mortality associated with
HIV [1,2]. However, the development of antiretroviral-resistant
HIV mutations remains one of the factors that can impair the
efficacy of cART [3,4]. Lopinavir/ritonavir (LPV/r), approved by
the FDA in September 2000 and in Europe in April 2001, has
been widely used in the management of treatment-experienced
patients. It represents one of the options for initiation of treatment
in antiretroviral-naı¨ve patients in resource-rich countries and first
choice for second-line treatment in resource-limited countries
[5–7]. Prediction of the impact of specific patterns of protease
mutations on the efficacy of ritonavir-boosted protease inhibitors
(PI/r) is complicated, as clinically relevant resistance generally
requires multiple mutations and can develop through the interplay
of major and minor mutations in a variety of patterns. Several
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genotypic interpretation scores for LPV/r have been developed
[8–14], but there is little consensus on their relative value and little
attempt has been made to date to create a set of meta-rules
standardized across interpretation systems (IS) [14]. In addition to
these scores, clinicians often consult web-based IS such as the
Agence nationale de recherches sur le SIDA (ANRS), REGA and Stanford
IS. One of the analyses of the TITAN trial attempted to
standardize the ‘cut-off levels’ used by seven currently proposed
IS to divide patients into those likely to have or not to have
reduced susceptibility to LPV/r and identified potentially more
sensitive cut-offs, although in the specific context of deciding
whether to use LPV/r or darunavir [15]. The common issue with
these IS is that they are mainly expert-based and although very
transparent about the mutations that are included, how each of
them are weighted and why, typically weights are not derived
using methods of statistical inference. In addition, the Stanford IS,
for example, makes the implicit assumption that there is a
marginal effect of each mutation for a specific drug which is the
same, regardless of other concomitantly detected mutations (i.e.
there are no interactions between mutations). These IS often differ
in the mutations ascribed to reduce or enhance susceptibility. In
general, the question of whether a score for specific antiretrovirals
could be derived from analyzing the correlation between genotypic
data and virological response using statistical methods which is
superior to currently existing expert-based IS remains largely
unanswered [16,17]. The aim of this analysis was two-fold: i) to
compare a small number of covariate selection strategies in the
linear regression framework, known to perform well for prediction
in the context of high dimensional data, ii) to use the best
performing covariate selection method to derive a new LPV/r
score and to compare its predictive value to that of available expert
web-based IS. In order to achieve this objective, we used the data
from two large, independent and well characterized cohort studies
of HIV-positive individuals in Europe: the EuroSIDA cohort and
the merged data of the UK Collaborative HIV Cohort (UK
CHIC) Study and the UK HIV Drug Resistance Database (UK
HDRD).
Materials and Methods
Dataset
Using the data of the patients in the EuroSIDA cohort and in
the UK CHIC Study, for whom genotypic data were stored in the
UK HDRD, we constructed a database of treatment change
episodes (TCE) similar to those used in other previous collabora-
tive studies [16–20]. Clinical data are collected in the 2 cohorts
following rigid criteria which have been extensively described in
detail elsewhere [21,22]. Briefly, all viral loads as well as dates of
starting and stopping all antiretroviral drugs are routinely collected
in all patients enrolled in these cohorts. EuroSIDA requests that
both genotypic tests performed at the clinical sites and plasma
samples are collected prospectively. Please see Information S1 for
study structure and contributing clinical sites in UK CHIC and
EuroSIDA cohorts.
Retrospective genotypic sequencing has been carried out on
samples identified for specific projects. HIV-1 RNA is isolated
from patient blood plasma using QIAamp kit (Qiagen, Barcelona,
Spain) and sequence analysis of HIV-1 RT and PR reading frames
is performed using the Trugene HIV-1 genotyping Kit and
OpenGene DNA Sequencing System according to the manufac-
turer’s recommendations (Bayer, Barcelona, Spain). Data on
resistance for the patients included in the UK CHIC cohort are
obtained through the linkage with the UK HDRD, which contains
information on genotypic resistance tests performed on behalf of
most HIV clinics in the UK. Mutations are identified by
comparison against a reference sequence of the subtype B isolate,
HXB2 in both databases.
All patients provided written consent to participate to UK
CHIC and EuroSIDA, following procedures in accordance with
the ethical standards of the responsible committee on human
experimentation and the Helsinki Declaration. Ethics approval
(for the use of the databases) from the Institutional Review Board
(IRB) at all institutions/hospitals where participants were recruited
and human experimentation was conducted was obtained. No
specific consent for inclusion in the current analysis was needed.
A TCE entailed any change in therapy in which a patient
initiated LPV/r with a viral load .400 copies/mL as part of a
combination including $2 antiretrovirals (cART) (although we
refer to ‘‘treatment change episodes’’ it should be noted that
initiations of lopinavir/r-based cART from ART-naı¨ve patients
are also included in this analysis and TCE could entail simply the
addition of LPV/r to a failing regimen). For each TCE we
recorded: all drugs initiated together with LPV/r, all drugs
currently received as part of cART, the viral load and the results of
a genotypic resistance test performed in the 6 months preceding
the initiation of LPV/r and a follow-up viral load measured over
the first 4 months from starting LPV/r. When multiple baseline or
follow up data were available, the value closest to month 3 after
initiation of LPV/r was used (Figure 1). Because only a minority of
patients (,5%) contributed more than one TCE (more than one
distinct combination of these 3 key TCE-defining features existed
at 2 or 3 time points) no attempt in the analysis was made to
correct for violation of independence of individual observations.
TCE including drugs not belonging to the 3 original major drug
classes (NRTI, NNRTI and PI) were not considered because only
RT and PR regions of HIV were sequenced. Using the results of
the genotypic tests we could generate a genotypic susceptibility
score (GSS) for all antiretrovirals started together with LPV/r
using the rules of ANRS IS (version 19) [23]. We also derived the
lopinavir predictions using the 3 most common expert-opinion
base IS (ANRS v19, Rega v8.0.2 [24] and Stanford v6.0.10 [25]).
To make predictions of Stanford comparable to the other 2 web-
based IS we grouped ‘‘potential low-level resistance’’ with
‘‘susceptible’’ and ‘‘low-level resistance’’ with ‘‘intermediate’’.
For this analysis, the UK CHIC/UK HDRD databases provided
the training/validation datasets (n = 1,174 TCEs) and EuroSIDA
provided the test dataset (n = 388 TCEs).
Figure 1. Description of a lopinavir-based TCE.
doi:10.1371/journal.pone.0025665.g001
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Statistical analysis
The main characteristics of the TCE were described after
stratification by cohort study. Because it is generally impossible to
know, a priori, which off-the-shelf machine learning/statistical
approaches will perform best for a given prediction problem and
data set, we used a standard linear regression model with
interaction terms for simplicity. The outcome was the change in
viral load from pre-TCE to post-TCE levels on the log10 scale. For
patients whose viral load decreased to undetectable levels we used
the naı¨ve approach of replacing the unobserved undetectable
value with the limit of detection of the assay used. In sensitivity
analyses, we instead replaced the unobserved undetectable value
with K of the limit or with the fixed value of 20 copies/mL.
The basic set of covariates (pre-LPV/r start viral load, exact
month of viral load response (ranging between 1 and 4 months)
and the ANRS predictions for the other drugs started besides
LPV/r were considered in all regression models but were not
forced into a model unless they were found to improve the
prediction performance according to the specific selection criterion
used. We then constructed 4 separate models including: i) the
LPV/r Rega GSS, ii) the LPV/r ANRS GSS, and iii) the LPV/r
Stanford GSS. All web-based GSS were fitted as categorical
variables with ‘‘susceptible’’ as the reference group. Model iv)
included individual PI mutations and 2-way interactions between
these rather than a specific susceptibility score. Candidate PI
mutations to be included were those reported as being a major
mutation with non-zero prevalence associated with PI-resistance in
either the IAS-USA December 2010 [26] list or any of the
considered web-based IS and minor mutations which were
detected with a prevalence .5% (see complete list in the Results).
Three different criteria for the selection of mutations and 2-way
interactions between mutation terms were used -best subset least
squared estimations (LSE), least absolute shrinkage and selection
operator (LASSO) [27] and a hybrid version of least angle
regression (LAR) and LASSO. The hybrid method is a
modification of the LAR originally proposed by Efron et al.
[28]. In this approach, the sequence of models is determined by
the original LAR algorithm but the coefficients of the parameters
for the model at any step are determined using ordinary least
squares. Both LASSO and LAR are shrinkage and selection
methods for linear regression which minimize the usual sum of
squared errors though with a bound on the sum of the absolute
values of the coefficients given by a complexity parameter (Table
S2). This parameter was chosen to minimize the average squared
error (ASE) based on a tenfold cross-validation (CV) on the UK
CHIC/UK HDRD TCE database. Briefly, 10-fold CV works by
dividing the dataset randomly into ten equal parts. The method
fits the model for a range of values of the complexity parameter to
nine-tenths of the data and then computes the prediction error on
the remaining one-tenth. This is done, in turn, for each one-tenth
of the data, and eventually the 10 prediction error estimates are
averaged. From this procedure we obtained an estimated
prediction of the 10-fold CV error (CV PRESS) curve as a
function of the model evolution steps which was used to establish
where to stop the inclusion of the covariates. In practical terms, the
‘‘one-standard-error’’ rule was used by picking the most
parsimonious model within one standard error of the minimum
CV PRESS. In contrast, the training set is used to determine the
coefficients but not to decide when to stop as the CV PRESS in
training decreases monotonically at each step regardless of the
number of steps.
Cross-validation was applied to the UK CHIC/UK HDRD
database (training/validation set) to select the complexity param-
eter for both LASSO and the hybrid version of LAR and LASSO.
In contrast, the EuroSIDA database (test set) was never used for
training but to judge the performance of the selected models. We
identified the mutations marginally associated with the outcome
first and then fitted a separate model incorporating all 2-way
interactions among this subset of mutations only. Although the
categorical variables for the predictions of ANRS, Rega and
Stanford IS were forced to remain in the corresponding models,
the other parameters to be included (from pre-TCE viral load,
GSS of other drugs and exact months from TCE to post-TCE
viral load) were selected using CV.
The performance of the models was tested by comparing the
magnitude of the ASE on the test dataset using analysis of variance
(ANOVA) with robust empirical estimates of the standard errors.
For completeness the R-Square on training and the ASE on both
training and validation were also shown. In addition, we
transformed the continuous outcome into a binary variable (using
the cut-off of reduction of .1.5 log copies/mL), calculated the
accuracy (i.e. the percentage of patients correctly classified) and
performed a likelihood ratio test to compare these percentages by
model from fitting a GEE Poisson regression model. All analyses
were performed using the procedure (for CV), MIXED (for
ANOVA) and GENMOD (for GEE) in SAS 9.2 (SAS Institute,
Cary, NC, USA, 2010).
Results
Table 1 shows the main characteristics of the TCE stratified by
training and test set. These characteristics were extremely similar
in the two cohorts. Viral load decreased by an average of 2.0 log10
copies/mL upon initiation of LPV/r. There was a small
percentage (,3%) of truncated changes in viral load due to the
response viral load being measured with an assay with lower limit
of 400 copies/mL and a substantially higher censoring below 50
copies/mL (30%). The majority of patients did not just add LPV/r
to an existing regimen but started a complete new regimen with an
average of 2 new nucleosides as well as LPV/r. The NRTI most
frequently used was lamivudine (45%). Fewer than 10% of patients
also started a NNRTI (mainly efavirenz). Median calendar year of
TCE was 2003 (range:1998–2008). Only 21 (5%) of the EuroSIDA
patients and 35 (3%) of those from UK CHIC contributed 2
TCEs.
Table 2 shows the extent of PI-resistance captured by the
genotype at the time of the TCE. A minority of patients show
mutations associated with major resistance to LPV/r. The most
prevalent of these mutations was V82F, detected in 5–8% of
patients respectively in UK CHIC/HDRD and EuroSIDA. This
lower prevalence was also reflected in the IS predictions
indicating, on average, that approximately 90% of patients carried
a virus which was susceptible to LPV/r regardless of the system
used. Over 50% of TCE include 2 other newly initiated drugs
which were predicted to be active by the ANRS IS. Among the
more polymorphic PI mutations (nevertheless included in the IAS-
USA December 2010 list as PI-resistance mutations) the most
prevalent ones were E35D, M36I, L63P and V91S reaching a
percentage ranging between 30% and 50%.
When we used the best subset selector, LSE estimates of the
coefficients and 10-fold CV to identify our model potentially
leading to a novel LPV/r score, besides pre-TCE viral load, 5
mutations were selected: I15V (parameter estimate = +0.13),
K20I (estimate =20.26), I54V (estimate =20.29), I62V (esti-
mate =20.11) V82A (estimate =20.60) and V91S (esti-
mate = +0.11). Figure 2 shows the relative importance of these
factors at each step of the selection process as well as provides
information as to when effects entered the model (the estimates -or
Derivation of a LPV/r Score with Linear Regression
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weights- above are derived directly from the standardized
coefficients at final step 7 and are summarized in Table 3, a
negative weight means a negative impact on viral response).
In contrast, the mutations included in the interpretation rules
for LPV/r of the 3 expert-based IS are shown in Table S1. Figure
S1 shows the evolution of the ASE at each step until final step 7
was reached and inclusion of factors terminated because the ten
error estimates computed by cross-validation (CV PRESS) stopped
showing a decrease using the ‘‘one-standard-error’’ rule. Step 7
was the chosen closing step for most of other fit criteria considered
(including AIC, BIC or adjusted R-square, Figure S2).
The ASE was greatly reduced when pre-TCE viral load entered
the model and additionally reduced when V82A entered the
model. The improvements in ASE after the introduction of viral
load is a key finding as it implies that the models including viral
load are a substantial improvement compared to the null model
(with intercept only) but that adding some of the genotypic
information further improves the predictive performance. Only
minor changes of the ASE were seen after further introducing the
other mutations on the training, validation, and test datasets. Note
that while, as expected, the ASE on the training data decreased
monotonically, the ASE on the validation set (the portions of UK
CHIC/HDRD which were not used for training) started to slightly
increase beyond step number four. This indicates that the models
after step 4 were beginning to overfit the training data. The ASE
on the test set was a lot larger than the validation ASE although
there was no sign of over-fitting.
Interestingly, neither the GSS for other drugs started with LPV/
r nor the exact month of viral load response were retained in the
final model of main effects. Two 2-way interactions were identified
to improve the fit of the models: I62V/A82V (weight of I62V
Table 1. Description of viral load and treatment in the TCE
database stratified by cohort.
Characteristics Dataset
UK CHIC/UK
HDRD EuroSIDA
N=1174 N=388
Pre-TCE viral load,
log10 copies/mL
Median (range) 4.63 (2.61, 7.18) 4.52 (2.63, 6.33)
Post-TCE viral load,
log10 copies/mL
Median (range) 2.00 (1.70, 6.15) 2.22 (0.78, 6.31)
Viral load reduction,
log10 copies/mL
Median (range) 2.17 (22.43, 5.21) 1.93 (21.80, 4.60)
% censored below
400 copies/mL, n(%)
26 (2.2%) 11 (2.8%)
% censored below 50
copies/mL, n(%)
440 (37.5%) 92 (23.7%)
Time from TCE to post-TCE
viral load, months
Median (range) 3 (1, 4) 3 (1, 4)
NRTI in regimen
at time of TCE
zidovudine 312 (26.6%) 78 (20.1%)
stavudine 214 (18.2%) 79 (20.4%)
lamivudine 565 (48.1%) 173 (44.6%)
emtrcitabine 85 (7.2%) 12 (3.1%)
tenofovir 576 (49.1%) 136 (35.1%)
didanosine 391 (33.3%) 154 (39.7%)
abacavir 340 (29.0%) 150 (38.7%)
NNRTI in regimen
at time of TCE
efavirenz 125 (10.6%) 73 (18.8%)
nevirapine 78 (6.6%) 32 (8.2%)
etravirine 5 (0.4%) 3 (0.8%)
PI in regimen
at time of TCE
saquinavir-HG 59 (5.0%) 23 (5.9%)
saquinavir-SG 10 (0.9%) 19 (4.9%)
indinavir 11 (0.9%) 30 (7.7%)
ritonavir 1174 (100%) 388 (100%)
amprenavir 26 (2.2%) 33 (8.5%)
atazanavir 14 (1.2%) 5 (1.3%)
darunavir 0 (0.0%) 1 (0.3%)
nelfinavir 15 (1.3%) 3 (0.8%)
No. new drugs started
at time of TCE
Median (range) 4 (3, 8) 3 (3, 7)
NRTI newly started
at time of TCE
zidovudine 276 (23.5%) 74 (19.1%)
stavudine 146 (12.4%) 67 (17.3%)
lamivudine 466 (39.7%) 119 (30.7%)
emtrcitabine 82 (7.0%) 12 (3.1%)
Characteristics Dataset
UK CHIC/UK
HDRD EuroSIDA
N=1174 N=388
tenofovir 511 (43.5%) 129 (33.2%)
didanosine 299 (25.5%) 140 (36.1%)
abacavir 285 (24.3%) 107 (27.6%)
NNRTI newly started at time of
TCE
efavirenz 109 (9.3%) 75 (19.3%)
nevirapine 61 (5.2%) 31 (8.0%)
etravirine 5 (0.4%) 3 (0.8%)
PI newly started at time of TCE
saquinavir-HG 39 (3.3%) 24 (6.2%)
saquinavir-SG 10 (0.9%) 19 (4.9%)
indinavir 6 (0.5%) 28 (7.2%)
ritonavir 1174 (100%) 388 (100%)
amprenavir 26 (2.2%) 33 (8.5%)
atazanavir 14 (1.2%) 4 (1.0%)
darunavir 0 (0.0%) 1 (0.3%)
nelfinavir 3 (0.3%) 3 (0.8%)
doi:10.1371/journal.pone.0025665.t001
Table 1. Cont.
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decreased to 20.51 when A82V was not detected) and I15V/
A82V (weight of I15V increased to +0.50 when A82V was not
detected, likelihood ratio test p = 0.0001). However, the introduc-
tion of these terms did not lead to a further decrease in ASE
(Table 4).
Both the LASSO and the LAR/LASSO models only include a
maximum of 3 main effects: pre-TCE viral load and mutation
V82A (LAR) and pre-TCE viral load and mutations I54V and
V82A (LASSO) as well as their interactions with viral load. Table 4
shows the comparison between the final ASE across the models
considered. All models seemed to perform equally well with little
difference in the ASE although the Rega algorithm seemed to
perform better both in validation and test datasets in the specific
cross-validation shown (ANOVA p-value on test p= 0.34). A
difference in ASE of 0.037 between Rega and Stanford
corresponds to a difference in root mean square error (RMSE)
of 0.19, meaning that the error in predictions (calculated as
predicted minus observed) between the two systems was of 0.19 log
copies/mL. Of note, the ASE on the test set was always larger than
the ASE on the validation set regardless of the model used. For
completeness, Table 4 also reports ASE and R-Squares in training.
As expected on average, the derived scores tended to perform
better in training although this tendency was reversed in the
validation and test set comparisons. All models seem to be able to
correctly classify 65% of participants and all performed equally
(p = 0.98). A sensitivity analysis conducted after replacing
unobserved undetectable viral load values with K of the limit of
lower detection or with the fixed value of 20 copies/mL, provided
similar results (data not shown).
Discussion
Increasingly complex prediction methods are used to try to
improve prediction of viral load response, in the light of existing
expert-based IS. The aim of this analysis was to assess a likely
incremental benefit of one of these more sophisticated approaches.
The availability of a well characterized TCE database extracted
from 2 large cohorts of HIV-positive patients in Europe gave us
the opportunity to explore some relatively novel methodologies for
Table 2. Description of HIV drug resistance prior to TCE
stratified by cohort.
HIV resistance Dataset
UK CHIC/UK
HDRD EuroSIDA
N=1174 N=388
Mutations in HIV
protease, n(%)
L10I 194 (16.5%) 61 (15.7%)
I13V 346 (29.5%) 52 (13.4%)
I15V 306 (26.1%) 49 (12.6%)
G16E 87 (7.4%) 3 (0.8%)
K20I 91 (7.8%) 15 (3.9%)
K20R 84 (7.2%) 38 (9.8%)
V32I 6 (0.5%) 10 (2.6%)
E35D 437 (37.2%) 65 (16.8%)
M36I 476 (40.5%) 80 (20.6%)
M46I 46 (3.9%) 43 (11.1%)
I47A 0 (0.0%) 0 (0.0%)
I47V 4 (0.3%) 7 (1.8%)
I54V 56 (4.8%) 34 (8.8%)
D60E 86 (7.3%) 16 (4.1%)
I62V 283 (24.1%) 80 (20.6%)
L63P 593 (50.5%) 120 (30.9%)
I64V 212 (18.1%) 36 (9.3%)
H69K 294 (25.0%) 18 (4.6%)
A71V 116 (9.9%) 53 (13.7%)
A71T 77 (6.6%) 17 (4.4%)
L76V 1 (0.1%) 2 (0.5%)
V77I 322 (27.4%) 49 (12.6%)
V82A 4 (0.3%) 8 (2.1%)
V82F 63 (5.4%) 32 (8.2%)
V82T 4 (0.3%) 10 (2.6%)
V82S 1 (0.1%) 1 (0.3%)
I84V 38 (3.2%) 23 (5.9%)
L89M 251 (21.4%) 16 (4.1%)
L90M 117 (10.0%) 64 (16.5%)
V91S 428 (36.5%) 89 (22.9%)
IS predictions, n(%)
ANRS lop/r
Susceptible 1129 (96.2%) 339 (87.4%)
Intermediate 36 (3.1%) 30 (7.7%)
Resistant 9 (0.8%) 19 (4.9%)
Rega lop/r
Susceptible 1115 (95.0%) 333 (85.8%)
Intermediate 49 (4.2%) 43 (11.1%)
Resistant 10 (0.9%) 12 (3.1%)
Stanford lop/r
Susceptible 1045 (89.0%) 306 (78.9%)
Intermediate 114 (9.7%) 72 (18.6%)
Resistant 15 (1.3%) 10 (2.6%)
HIV resistance Dataset
UK CHIC/UK
HDRD EuroSIDA
N=1174 N=388
ANRS GSS other drugs
(predicted no. of active)
0 32 (2.7%) 30 (7.7%)
0.5 46 (3.9%) 13 (3.4%)
1 253 (21.6%) 44 (11.3%)
1.5 63 (5.4%) 16 (4.1%)
2 651 (55.5%) 218 (56.2%)
2.5 14 (1.2%) 1 (0.3%)
3 102 (8.7%) 55 (14.2%)
.3 13 (1.1%) 11 (2.8%)
In bold major IAS-USA December 2010 mutations for lopinavir/r.
doi:10.1371/journal.pone.0025665.t002
Table 2. Cont.
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the construction of statistically-based IS such as LAR and LASSO
in the context of linear regression.
The first main result of our analysis is that in our example of
lopinavir-based TCE the performance of a model based on linear
regression was similar to that obtainable by currently available
largely expert-opinion based IS. If anything, the use of the Rega IS
seemed to provide better predictions on both validation and test
datasets than linear regression even when predictors were selected
with the more efficient LASSO criterion. Similar conclusions were
previously drawn by other authors performing almost identical
analyses although not in the context of LPV/r resistance and using
a binary viral load outcome [17,18]. In practical terms, after
transforming the continuous outcome into a binary variable
indicating failure (#1.5 log copies/mL viral reduction from
baseline) or success (.1.5 reduction) all models seemed to be able
to correctly classify 65% of the participants.
A second main result was the fact that adding interaction terms
to our model did not improve the predictions. This finding has
potentially two implications: the assumption made by web-expert
opinions (e.g. Stanford) that there is no interaction between
mutations for LPV/r and that mutations can be given a single
weight for their marginal effect may be valid. Indeed, in our
analysis whilst we found evidence that the weight for mutation
I62V should be different according to whether A82V was also
detected, the incorporation of this information did not lead to an
improvement in predictions. Although not proved by this analysis,
the second implication is that other commonly used non-
parametric non-linear approaches (such as random forests or
neural networks) are also unlikely to lead to improved perfor-
mance in this specific analysis; indeed, preliminary work based on
this dataset (data not shown) and others had already suggested this
point [17]. Of note, the exact time of the post-cART viral load
measurement was a covariate which was not retained in any of the
final models. A possible interpretation of this finding is that the
viral drop upon initiation of a lopinavir-containing regimen is
similar regardless of whether it is measured 1 month or up to 4
months from starting the drug, consistent with the view that it is a
potent protease inhibitor.
Third, the results derived from cross-validation only tell part of
the story. This is because, as previously shown, TCEs coming from
a single source tend to be more similar to each other than TCEs
coming from completely distinct settings [19]. In our analysis this
was clearly shown by the large increase of the ASE in the test
dataset (consisting of patients from EuroSIDA) as opposed to
validation dataset (patients from the UK CHIC Study) and
suggests an inherent limitation of statistical-derived IS aiming at
predicting response in individuals who did not provide data for
training. Reasons for this discrepancy are unclear. In the analysis
by Assoumou et al [19], some of the variability seemed to be
explained by differences in the treatment history of the populations
enrolled in the different cohorts, which influenced the baseline
viral genotypes and by antiretroviral treatment strategies which
differed from one country to another. However, we did not detect
large differences between UK CHIC and EuroSIDA in these
Figure 2. Plot of the standardized coefficients of all the factors selected at each step (from step 1 to final step 7) of the best subset
(LSE) method are plotted as a function of the step number. This enables to assess the relative importance of each factor selected at any step
of the selection process as well as provides information as to when effects entered the model. The lower plot in the panel shows how CV PRESS (the
criterion used to choose the selected model) changes as factors enter or leave the model. Selection was halted at step 7 when the ‘‘one-standard
error’’ rule was achieved.
doi:10.1371/journal.pone.0025665.g002
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parameters. It can also be argued that both EuroSIDA and UK
CHIC are themselves an amalgam of data from diverse clinical
sites although collected in a similar standardized way. The
external validation using the EuroSIDA database (a completely
independent dataset) is an important feature of this analysis which
has rarely been employed in previous similar analyses [17,29].
Several LPV/r scores have been constructed in recent years.
One of the first LPV/r mutation scores was developed by
comparing the genotypes and phenotypes of 112 viral isolates from
early clinical trials [8]. Mutations at 11 amino acid positions in
protease were found to be correlated with increased phenotypic
resistance to LPV/r. Another weighted score was developed using
1,482 clinical samples available from the Monogram Biosciences
database, for which both a genotype and phenotype for LPV/r
had been performed [9] and validated in another analysis [10].
This score consists of 29 mutations at 18 protease positions and
viruses with a score $7 were considered to have reduced
susceptibility to LPV/r. Although this score was based on many
more isolates than the LPV/r mutation score, the investigators
were limited to making genotype-phenotype correlations. A large
Table 3. Coefficients (standard errors) associated with covariates included in the model.
Interpretation
system Mutations, susceptibility scores and interaction effects coefficient (se)
I15V K20I I54V I62V V82A V91S I62V*V82A I15V*V82A VL*I54V VL*V82A I R
Model i) ANRS 2.74
(0.18)
21.46
(0.37)
Model ii) Rega 2.61
(0.16)
21.74
(0.34)
Model iii)
Stanford
2.29
(0.11)
21.38
(0.27)
Model iv) Best
subset LSE
main effects
+.13 (0.07) 2.26
(0.13)
2.29
(0.18)
2.11
(0.08)
2.60 (0.17) +.11 (0.07)
Best subset
LSE main
effects+2 ways
interactions
+.10 (0.07) 2.24
(0.12)
2.28
(0.18)
2.10
(0.08)
+1.89 (0.77) +.13 (0.07) 2.51 (0.34) 2.13 (0.07)
LASSO main
effects
2.12
(0.08)
2.36 (0.21)
LASSO viral load+2
ways interactions
2.07 (0.01) 2.13 (0.08)
LAR/LASSO main
effect
2.80 (0.15)
LAR/LASSO viral
load+2 ways
interaction
2.17 (0.07)
I = Intermediate, R = Resistant.
doi:10.1371/journal.pone.0025665.t003
Table 4. Average squared error, R-squares and accuracy according to selection criteria on the training, validation, and test datasets
at final inclusion step.
Training Validation Test (EuroSIDA)
Interpretation system ASE R-Square ASE ASE* Accuracy**
Model i) ANRS 1.037 0.354 1.207 1.299 0.655
Model ii) Rega 1.074 0.359 0.786 1.258 0.647
Model iii) Stanford 1.059 0.336 1.048 1.295 0.655
Model iv) Best subset LSE main effects 1.032 0.370 1.124 1.330 0.657
Best subset LSE main effects+2 ways interactions 1.018 0.379 1.132 1.338 0.662
LASSO main effects 1.063 0.352 1.109 1.315 0.650
LASSO main effects+2 ways interactions 1.041 0.365 1.130 1.326 0.650
LAR/LASSO main effects 1.051 0.359 1.135 1.374 0.655
LAR/LASSO main effects+2 ways interactions 1.044 0.363 1.136 1.372 0.655
*ANOVA p-value for the difference between models p = 0.34.
**Percentage correctly classified as successes (viral load drop .1.5 log copies/mL) or failures (viral load drop #1.5 log copies/mL); likelihood ratio test p-value from
fitting a GEE model p = 0.98.
doi:10.1371/journal.pone.0025665.t004
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database from France (the ATU database) was used to evaluate the
virological response to LPV/r in 792 treatment-experienced
individuals and generated a LPV/r score [11]. Within the ATU
dataset, mutations at 10 amino acid positions in protease were
found to better predict virological response than the previously
described scores. Some authors proposed and showed the potential
utility of genotypic inhibitory quotients (GIQ) based on the ratio
between LPV/r concentration and number of LPV/r resistance
mutations) [30–32] although due to lack of consensus on which list
of mutations to use, the predictive value of GIQ varies according
to the IS used [32].
Regarding the mutations included in our LPV/r score, besides
mutations I15V and V91S which seemed to be not currently
recognized polymorphisms associated with a better response to
LPV/r, V82A is listed by IAS-USA December 2010 as a major
LPV/r mutation and used in the rules of all previously developed
scores (Abbott 2007 score [12] ANRS and Rega IS [23,24] and
Food and Drug Association (FDA) LPV/r mutations list [13]). In
the Stanford IS this mutation is currently given a weight of +25
which is the 2nd highest weight, after that given to I47A
(weight =+50) while the Rega IS assign a weight of 0.6,
remarkably similar to ours but about half the weight given to
I54V (Table S1). Interestingly, mutation V82A was the first to be
entered in our model leading to the largest decrease in ASE
besides pre-TCE viral load while V82F which was more prevalent
than V82A was not selected at all. Mutations K20I and I54V were
given smaller weights in our score which is consistent with the fact
that are not major IAS-USA mutations but are listed in most
available IS (I54V is not included in ANRS). Finally I62V seemed
to have a marginal negative impact on viral response, especially
when detected in the absence of V82A. Unfortunately we do not
have phenotypic evidence to support this finding (it is scored as
zero in all web-based IS –Table S1- and whilst sometimes
associated with resistance to saquinavir or fosamprenavir [23]
seems to be quite polymorphic). Of note, the weight of I62V was
shrunk to zero by the LASSO procedure suggesting that this was a
spurious association due to chance alone.
Some limitations of this analysis need to be discussed. First of
all, in a setting in which viral load measures are truncated by the
lower limit of the assay, binary outcomes are typically preferred.
Although the percentage of censored response viral load was
relatively low we may have introduced bias by replacing this
unobserved value with the lower limit of detection of the assay.
However, when we performed a sensitivity analysis by replacing
the unobserved undetectable viral load values with K of the limit
of lower detection or with the fixed value of 20 copies/mL results
were similar. We did not choose to evaluate a wider range of
statistical approaches for three main reasons: i) the performance of
specific approaches is likely to vary according to the specific
features of the dataset analyzed and therefore a unique ‘‘best
predictive model’’ may not exist; ii) previous attempts to identify
the best approach have reached discordant conclusions [17,18,20]
and iii) linear regression is simple to implement in SAS (a robustly
validated statistical package), easy to interpret and has been
previously shown to have high predictive power in the field of HIV
resistance [33]. The prevalence of some of the mutations
considered key for lopinavir/r by expert opinion (e.g. V32I,
I47V, L76V) was relatively low and this could have influenced the
covariate selection for our score. Furthermore, we have only
considered PI mutations previously found to be associated with
reduced susceptibility to PI, thus we cannot exclude the possibility
that our model could be outperformed by another one constructed
using all changes from consensus in the PR region. Nevertheless,
this addition would add further complexity and it is beyond the
scope of the current exercise. We aim to repeat this analysis using
a larger dataset including all major cohort studies in Europe.
Similarly, one of the limitations of predictive systems is that
population sequence assays only detect mutations present in major
quasi-species. Indeed it has been shown that the inclusion of other
information coming from ultra-deep sequencing, phenotypic data,
genetic barrier of resistance, phylogenetic-type analyses or even
drug history can significantly improve the predictive capability of a
given model [28,34–39]. Unfortunately besides drug history,
which was not considered, none of these data are yet available in
our cohorts. Other unmeasured factors such as adherence, known
to be associated with the level of resistance, could have
confounded the association between specific mutations and
outcome.
LPV/r was for quite some time the standard boosted PI for
treatment-experienced patients with PI-related resistance muta-
tions. However, with the approval of other drugs such as tipranavir
and particularly darunavir and atazanavir/r, it has become
increasingly important for clinicians to be able to choose between
these newer PI/r and LPV/r for these patients. Our analysis does
not directly address the question of which PI/r should be used and
in which circumstances, but suggests that the choice of LPV/r can
successfully rely on currently available web-based IS predictions.
In conclusion, we fully explored the potential of linear
regression to construct a simple predictive model for LPV/r-
based TCE. Two of the identified mutations (V82A ad I54V) in
our score are recognized LPV/r mutations listed by widely used
expert-based IS. In addition, we identified previously unrecog-
nized mutations I62V ad K20I, which appear to have a modest
impact in reducing viral response, and mutations I15V and V91S
which, in contrast, seem to determine LPV/r hypersensitivity, all
of which need further investigation. Although, the performance of
our proposed score seems to be similar to that of already existing
IS, the same approach of validation of web-based IS could be used
in the future for other antiretrovirals ideally including a larger
number of TCE and in other settings outside HIV research.
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Figure S1 Evolution of the average squared error (ASE)
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coefficients over the 7 steps at which a new factor has
been introduced in the model.
(TIF)
Figure S2 Sequence of models and stopping step
according to model fit statistics used; the sum of the
10 predicted residual sum of squares from the cross-
validation (CV PRESS) was the criterion chosen for this
analysis.
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for our score.
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